Skip Navigation


International Immunology Advance Access originally published online on September 1, 2005
International Immunology 2005 17(10):1315-1325; doi:10.1093/intimm/dxh309
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/10/1315    most recent
dxh309v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Elkord, E.
Right arrow Articles by Rowbottom, A. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Elkord, E.
Right arrow Articles by Rowbottom, A. W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Japanese Society for Immunology. 2005. All rights reserved. For permissions, please e-mail: journals.permissions@oupjournals.org

Differential CTLs specific for prostate-specific antigen in healthy donors and patients with prostate cancer

Eyad Elkord1,4, Paul E. Williams1,2, Howard Kynaston3 and Anthony W. Rowbottom2

1 Department of Medical Biochemistry and Immunology, School of Medicine, Cardiff University, Cardiff, UK
2 Department of Medical Biochemistry and Immunology and 3 Department of Urology, University Hospital of Wales, Cardiff, UK
4 Present address: CRUK Immunology Department, Paterson Institute for Cancer Research, Manchester M20 4BX, UK

Correspondence to: E. Elkord; E-mail: eelkord{at}picr.man.ac.uk

Induction of CTL responses specific for prostate-specific antigen (PSA)-derived peptides in healthy individuals and patients with prostate cancer (PC) was investigated. Eight PSA-derived peptides that have the potential to bind HLA-A2 molecules were examined. Peripheral blood lymphocytes isolated from HLA-A2-positive volunteers were expanded using autologous mature, PSA-derived peptide-pulsed dendritic cells. The expansion of IFN-{gamma}-secreting CD8+ T cells specific for three of the eight PSA-derived peptides (PSA-2108–117, PSA-4141–150 and PSA-6146–154) was detected in healthy individuals, but not in patients with PC. Using HLA-A2/peptide tetramers, the PSA-specific CD8+ T cells were detectable at low frequency both in healthy individuals and patients with PC. Using flow cytometric cytotoxicity assays, the expanded effectors from healthy individuals were able to kill the PSA-expressing epithelial cell line LNCaP and the peptide-pulsed T2 cells in a MHC class I-restricted manner without involving NK activity. However, such killing by effectors expanded from prostatectomized patients involved a complete or a significant NK activity. Specific recognition of PSA-derived peptides in healthy individuals may occur by an adaptive CTL immune response, while such recognition in PC patients may additionally or alternatively be mediated by an innate NK immune response. In conclusion, our work indicates that the PSA-specific CD8+ T cells exist in both healthy individuals and PC patients, but they have impaired function in patients as they failed to release IFN-{gamma} and to kill targets without involving NK activity.

Keywords: cytotoxic T lymphocytes, dendritic cells, NK activity, prostate cancer, prostate-specific antigen

Transmitting editor: E. Simpson


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.